Sevabertinib-related diarrhea in HER2-mutated NSCLC is generally low-grade and manageable, study shows

The SOHO-01 trial examined the safety of sevabertinib in patients with HER2-mutated non-small cell lung cancer, focusing on treatment-related diarrhea.

Diarrhea occurred frequently but was mostly low-grade and of short duration. Severe cases were uncommon.

Standard supportive care and dose adjustments were effective in controlling the symptom, allowing most patients to stay on therapy.

The analysis also indicated that patients' prior treatments and higher drug exposure might increase the risk of more serious diarrhea, offering guidance for clinicians.